UBS Maintains Neutral on Intra-Cellular Therapies, Lowers Price Target to $79
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Ashwani Verma maintains a Neutral rating on Intra-Cellular Therapies (NASDAQ:ITCI) but lowers the price target from $83 to $79.
August 08, 2024 | 2:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
UBS analyst Ashwani Verma maintains a Neutral rating on Intra-Cellular Therapies (NASDAQ:ITCI) but lowers the price target from $83 to $79.
The lowered price target from $83 to $79 by UBS suggests a less optimistic outlook for Intra-Cellular Therapies, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100